RxDoctor Payments Data

Jessica Valdez

Pediatric Hematology-Oncology · Albuquerque, NMNPI 1750673661

Payments from drug & device makers

What this record shows

Day One Biopharmaceuticals accounts for 65.8% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $1,910, more than ten times the $124 reported in 2019.

$2,764in general payments, 2019–2025

Across 17 payments — averaging $162.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Day One Biopharmaceuticals$2K
  • Jazz Pharmaceuticals Inc.$345
  • Adaptive Biotechnologies Corporation$190
  • Genentech USA, Inc.$124
  • USWM, LLC$119
  • BTG International Inc.$118
  • plus $50 from 2 others
$344,560in research payments, 2019–2025

Across 17 payments — averaging $20,268 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Incyte Corporation$342K
  • E.r. Squibb & Sons, L.L.C.$3K

What the payments were for

  • Consulting fees$1,59058%
  • Food & beverage$1,17442%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric hematology-oncology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.

Other pediatric hematology-oncology in Albuquerque

Where these figures come from

Is this you, or does something look wrong? →